After three more diagnoses and five weeks of recovery, I’m thrilled to be back writing columns. Over the past year, I’ve documented my journey to finding solutions to my increasing pain levels. At first, my medical team agreed that a large part of my pain stemmed from hypoparathyroidism…
Discussion
Soft morning light spills through my windows as I power on my laptop. A gentle glow envelops the quiet room. I think about where I was a year ago, when hope felt uncertain and struggle was heavy. April marks the first anniversary of my column, “Brave Butterfly,” so I…
Single doses of canvuparatide, an injectable hormone replacement treatment being developed by MBX Biosciences for chronic hypoparathyroidism, appeared to be safe in healthy adults and were long-acting in the bloodstream, supporting the once-weekly dosing regimen now being tested in later-stage trials. These data come from the first…
MBX Biosciences is advancing its experimental therapy canvuparatide (MBX 2109) toward a Phase 3 trial in adults with chronic hypoparathyroidism, following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). An End-of-Phase 2 meeting is typically held after a Phase 2 study to determine whether a…
Get regular updates to your inbox.
